COLLEGIUM PHARMACEUTICAL, INC (COLL): debt financing — Collegium prices $241.5M convertible notes offering, repurchases $117.4M of 2026 notes

COLLEGIUM PHARMACEUTICAL, INC

Priced $210M convertible notes offering, upsized to $241.5M with full exercise of initial purchasers' option.
Notes bear 2.875% interest, mature Feb 2029; initial conversion price $36.56/share, ~30% premium to $28.12.
Net proceeds estimated at $203.2M ($233.8M if greenshoe fully exercised) after discounts and expenses.
Used $140.1M to repurchase $117.4M of its 2.625% convertible notes due 2026.
Remainder for general corporate purposes including business development and capital allocation.

item 1.01 item 2.03 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

COLLEGIUM PHARMACEUTICAL, INC incurred convertible notes of $241,500,000 principal amount with The Bank of New York Mellon Trust Company, N.A. at 2.875% per annum maturing February 15, 2029.

Instrument: convertible notes
Principal: $241,500,000 principal amount
Counterparty: The Bank of New York Mellon Trust Company, N.A.
Rate: 2.875% per annum
Maturity: February 15, 2029
Event: incurrence

Exact text from the filing

On February 10, 2023, Collegium Pharmaceutical, Inc. (the “ Company ”) issued $241,500,000 principal amount of its 2.875% Convertible Senior Notes due 2029 (the “ Notes ”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

COLLEGIUM PHARMACEUTICAL, INC entered into 2.875% Convertible Senior Notes due 2029 Indenture with The Bank of New York Mellon Trust Company, N.A. valued at $241,500,000 principal amount of 2.875% Convertible Senior Notes due 2029 (effective 2023-02-10).

Action: entry
Agreement: notes offering
Counterparty: The Bank of New York Mellon Trust Company, N.A.
Value: $241,500,000 principal amount of 2.875% Convertible Senior Notes due 2029
Effective: 2023-02-10

Exact text from the filing

On February 10, 2023, Collegium Pharmaceutical, Inc. (the “ Company ”) issued $241,500,000 principal amount of its 2.875% Convertible Senior Notes due 2029 (the “ Notes ”). The Notes were issued pursuant to, and are governed by, an indenture (the “ Indenture ”), dated as of February 10, 2023, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “ Trustee ”).

View on SEC.gov

102 debt financings filed in the last 30 days. Browse all debt financings →

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001104659-23-019671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.